Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Short report TH

<< Previous

Bullboard Posts

Next >>

Comment by Spartrapon Jan 21, 2021 11:26am

140 Views

Post# 32345028

RE:RE:RE:Short report TH

Well since then we learned the underwritters could place all the overallotment at the intended price, regardless of the drop, and the company issued the shares for it, so no, sorry, no big short to cover on the market from the bankers *shrug*

scarlet1967 wrote: I had that discussion with Spartrap on Stocktwits and below was his idea which is another way to lol at it.
"Overallotment will simply be sold short to clients while the bankers cover on the open market at below offering price. Which also happens to stabilize the price back up again. They have 2,175,000 shares of flexibility to do so (15% of offering)"

jeffm34 wrote: Did the new investors short the stock from $4.20 down to $3.50 during the run up knowing they had shares coming at $3.50 to cover?